Beam Therapeutics BEAM
NASDAQ BEAM
$29.64 +0.18 (+0.61%)
As of: Sep 4, 2026 · 3:59 PM EDT

Beam Therapeutics (BEAM) Acquisitions (2021)

Beam Therapeutics (BEAM) posted quarterly Acquisitions of $620000.0 for Q1 2021.

Analysis

Beam Therapeutics (BEAM) Acquisitions (2021) Analysis & Trends

Beam Therapeutics (BEAM) has reported Acquisitions for 1 consecutive years, with $620000.0 the latest figure, recorded in Q1 2021.

  • In Q1 2021, Acquisitions changed N/A year-over-year to $620000.0; the TTM figure through Dec 2021 stood at $620000.0 (changed N/A YoY), while the FY2025 annual figure was $78000.0, changed N/A from the prior year.
  • Acquisitions steadied at $620000.0 in Q1 2021 per BEAM's latest filing.
  • Across five years, Acquisitions topped out at $620000.0 in Q1 2021 and bottomed at $620000.0 in Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Beam Therapeutics 3.10 Bn 3.10 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 620,000.00